Perspective Therapeutics Inc   (CATX)
Other Ticker:  
Price: $1.4900 $-0.10 -6.289%
Day's High: $1.58 Week Perf: -2.61 %
Day's Low: $ 1.43 30 Day Perf: -12.35 %
Volume (M): 3,055 52 Wk High: $ 1.90
Volume (M$): $ 4,551 52 Wk Avg: $0.70
Open: $1.58 52 Wk Low: $0.21

 Market Capitalization (Millions $) 408
 Shares Outstanding (Millions) 274
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 1

Perspective Therapeutics Inc
Perspective Therapeutics Inc is a biotech company that focuses on developing innovative therapies for various diseases and medical conditions. The company's goal is to provide groundbreaking solutions that improve patient outcomes and quality of life.

They specialize in developing therapeutics that target specific biological pathways and mechanisms to address the underlying causes of diseases. The company's research and development efforts encompass a wide range of therapeutic areas, including oncology, neurology, immunology, and rare genetic disorders.

Perspective Therapeutics Inc utilizes advanced technologies and scientific approaches to identify and develop small molecule drugs, biologics, and gene therapies. The company collaborates with leading academic institutions, research organizations, and pharmaceutical companies to leverage their collective expertise and resources.

Their team consists of experienced scientists, researchers, and clinicians who are dedicated to translating scientific discoveries into clinically relevant treatment options. The company's approach is rooted in rigorous scientific research, preclinical studies, and clinical trials to ensure the safety and efficacy of their therapeutic candidates.

Perspective Therapeutics Inc aims to make a significant impact on the healthcare industry by introducing new and effective treatment options for patients worldwide. Ultimately, their mission is to improve the lives of individuals affected by challenging diseases through innovative therapies that address unmet medical needs.

   Company Address: 2401 Elliott Avenue, Suite 320 Seattle 98121 WA
   Company Phone Number: 676-0900   Stock Exchange / Ticker: NYSE CATX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


Perspective Therapeutics' Leadership Team Set to Engage with Investors at Upcoming May Conferences

Published Fri, May 3 2024 11:00 AM UTC

Seattle-based Perspective Therapeutics, Inc. has announced that its senior leadership team is set to participate in several investor conferences slated for May. The radiopharmaceutical company, a player in the medical industry pioneering advanced treatment avenues for various forms of cancer, disseminated this information in a statement on May 3, 2024.This participation is a...


Perspective Therapeutics Set to Report Strong Financial Results and Showcase Progress in Pioneering Cancer Treatments

Published Thu, May 2 2024 11:00 AM UTC

Perspective Therapeutics, a pioneering radiopharmaceutical company specializing in advanced cancer treatments, is set to provide an update on its recent business highlights and report its first quarter 2024 financial results on May 15, 2024. This announcement comes after the company successfully closed a public offering, raising approximately $69.0 million in gross proceeds....


FDA Boosts Perspective Therapeutics' Innovative Cancer Treatment: A Leap Forward in Accelerating NETs Therapy

Published Tue, Apr 30 2024 11:00 AM UTC

The company revealed the news on April 30, 2024, drawing attention to its continued pioneering efforts in creating advanced therapeutic applications for various forms of cancer. The FDA?s decision to include Perspective Therapeutics and their revolutionary treatment in the CDRP program gives a nod to their commendable work in this field, as well as their potential to create ...


Perspective Therapeutics Secures $87.4 Million in Private Placement to Drive Innovative Cancer Treatments

Published Mon, Mar 4 2024 2:45 PM UTC

In a significant development, Perspective Therapeutics, a pioneering radiopharmaceutical company, announced an investment agreement with a group of institutional accredited investors. The company aims to raise approximately $87.4 million through a private placement, with the proceeds dedicated to advancing their advanced treatment applications for cancers across the body. Th...


Perspective Therapeutics Scores Financial Triumph with $69.0 Million Public Offering and $20.8 Million Private Placement, Fuelling the Fight Against Cancer

Published Mon, Jan 22 2024 9:05 PM UTC

Operating under its company label on the NYSE American as CATX, Perspective Therapeutics confidently strides on its quest to innovate and revolutionize the realm of cancer therapeutics through its adept usage of medical isotopes. These often overlooked miracles of modern medical science provide an opportunity for significant advancements in the targeted delivery of radiation...


Perspective Therapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Perspective Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Perspective Therapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com